REFRaME-O1/ENGOT-OV79/GOG-3086: A Phase II/III, Open-Label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice of Chemotherapy in Women with Relapsed Platinum-Resistant Epithelial Ovarian Cancer Expressing Folate Receptor Alpha